Elsevier

Clinical Immunology

Volume 93, Issue 3, December 1999, Pages 198-208
Clinical Immunology

Short Analytical Review
Mechanism of Action for Leflunomide in Rheumatoid Arthritis

https://doi.org/10.1006/clim.1999.4777Get rights and content

Abstract

Leflunomide (Arava) has recently been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis (RA). This approval was based on data from a double-blind, multicenter trials in the United States (leflunomide versus methotrexate versus placebo) in which leflunomide was superior to placebo and similar to methotrexate (Strand et al., Arch. Intern. Med., in press, 1999). In a multicenter European trial, leflunomide was similar to sulfasalazine in efficacy and side effects (Smolen et al., Lancet 353, 259–266, 1999). Both methotrexate and leflunomide retarded the rate of radiolographic progression, entitling them to qualify as disease-modifying agents (Strand et al., Arch. Intern. Med., in press, 1999). Leflunomide is an immunomodulatory drug that may exert its effects by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), which plays a key role in the de novo synthesis of the pyrimidine ribonucleotide uridine monophosphate (rUMP). The inhibition of human DHODH by A77 1726, the active metabolite of leflunomide, occurs at levels (approximately 600 nM) that are achieved during treatment of RA. We propose that leflunomide prevents the expansion of activated and autoimmune lymphocytes by interfering with the cell cycle progression due to inadequate production of rUMP and utilizing mechanisms involving p53. The relative lack of toxicity of A77 1726 on nonlymphoid cells may be due to the ability of these cells to fulfill their ribonucleotide requirements by use of salvage pyrimidine pathway, which makes them less dependent on de novo synthesis.

References (77)

  • A.J. Levine

    p53, the cellular gatekeeper for growth and division

    Cell

    (1997)
  • R. Weinberg

    The retinoblastoma protein and cell cycle control

    Cell

    (1995)
  • C. Deng et al.

    Mice lacking p21 undergo normal development, but are defective in G1 checkpoint control

    Cell

    (1995)
  • D.R. Green et al.

    Activation-induced apoptosis in lymphocytes

    Curr. Opin. Immunol.

    (1994)
  • K. Ruckemann et al.

    Leflunomide inhibits pyrimidine de novo synthesis in mitogen stimulated T-lymphocytes from healthy humans

    J. Biol. Chem.

    (1998)
  • R.A. Williamson et al.

    Dihydroorotate dehydrogenase is a high affinity binding protein for A77-1726 and mediator of a range of biological effects of the immunomodulatory compound

    J. Biol. Chem.

    (1995)
  • S. Greene et al.

    Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

    Biochem. Pharmacol.

    (1995)
  • B. Bader et al.

    Expression, purification, and characterization of histidine-tagged rat and human flavoenzyme dihydroorotate dehydrogenase

    Protein Exp. Purif.

    (1998)
  • H.T. Silva et al.

    In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis

    Transplant. Proc.

    (1997)
  • A.N. Theofilopoulos

    The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition

    Immunol. Today

    (1995)
  • I. Kirsch et al.

    Lymphocyte-specific genomic instability

    Semin. Immunol.

    (1997)
  • C. Pally et al.

    Side effects of brequinar and brequinar analogues, in combination with cyclosporine in the rat

    Toxicology

    (1998)
  • X. Xu et al.

    Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide

    J. Biol. Chem.

    (1995)
  • V. Strand et al.

    Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate

    Arch. Int. Med.

    (1999)
  • W. Cao et al.

    Mechanism of the anti-proliferative action of leflunomide

    J. Heart Lung Trans.

    (1995)
  • S. Popovic et al.

    Disease modifying activity of HWA 486 on the development of SLE in the MRL/lpr mouse

    Agents Actions

    (1986)
  • S. Popovic et al.

    The use of the murine chronic graft-vs-host (CGVH) disease, a model for systemic lupus erythematosus (SLE) for drug discovery

    Agent Actions

    (1987)
  • T. Glant et al.

    Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide

    Immunopharmacology

    (1991)
  • S. Stosic-Grujicic et al.

    A novel immunomodulating agent—leflunomide inhibits experimental autoimmune diabetes in mice

    Transplant Proc.

    (1996)
  • R. Bartlett et al.

    Immunopharmacologic properties of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjunvant arthritis in the rat

    Int. J. Immunopharmacol.

    (1988)
  • R.R. Bartlett et al.

    Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis

    Transplant. Proc.

    (1996)
  • V. Mladenovic et al.

    Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis

    Arthritis Rheum.

    (1995)
  • M. Weinblatt et al.

    Leflunomide plus methotrexate in refractory rheumatoid arthritis: A pilot study

    Arthritis Rheum.

    (1999)
  • H.M. Cherwinski et al.

    The immunosuppressant leflunomide inhibits the progression through the cell cycle by a novel mechanism

    J. Pharm. Exp. Therapeutics

    (1995)
  • H.T. Silva et al.

    Mechanism of action of leflunomide: In vivo uridine administration reverses its inhibition of lymphocyte proliferation

    Transplant. Proc.

    (1996)
  • K.F. Siemasko et al.

    Regulation of B cell function by the immunosuppressive agent leflunomide

    Transplantation

    (1996)
  • R. Morris et al.

    Leflunomide (HWA 486) and its analog suppress T and B-cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey recipients

    Transplant. Proc.

    (1995)
  • S.P. Linke et al.

    A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage

    Genes Dev.

    (1996)
  • Cited by (0)

    View full text